Publication:
Clinical Characterization and Diagnostic Approaches for Patients Reporting Hypersensitivity Reactions to Quinolones.

dc.contributor.authorDoña, Inmaculada
dc.contributor.authorPerez-Sanchez, Natalia
dc.contributor.authorSalas, Maria
dc.contributor.authorBarrionuevo, Esther
dc.contributor.authorRuiz-San Francisco, Arturo
dc.contributor.authorHernandez-Fernandez-de-Rojas, Dolores
dc.contributor.authorMarti-Garrido, Jaume
dc.contributor.authorAndreu-Ros, Inmaculada
dc.contributor.authorLopez-Salgueiro, Ramon
dc.contributor.authorMoreno, Esther
dc.contributor.authorTorres, Maria Jose
dc.contributor.funderRETIC
dc.contributor.funderARADYAL
dc.contributor.funderConsejería de Salud of the Andalusian government, Junta de Andalucía
dc.contributor.funderInstitute of Health “Carlos III"
dc.contributor.funderSpanish Ministry of Economy and Competitiveness
dc.contributor.funderEuropean Social Fund
dc.date.accessioned2023-02-08T14:49:16Z
dc.date.available2023-02-08T14:49:16Z
dc.date.issued2020-05-04
dc.description.abstractQuinolones are the second most frequent cause of hypersensitivity reactions (HSRs) to antibiotics. A marked increase in the number of patients with HSRs to quinolones has been detected. To describe the clinical characteristics of patients with HSRs to quinolones and present methods for their diagnosis. Patients attending the allergy unit due to reactions suggestive of HSRs to quinolones were prospectively evaluated between 2005 and 2018. Diagnosis was achieved using clinical history, skin tests (STs), basophil activation tests (BATs), and drug provocation tests (DPTs) if ST and BAT results were negative. We included 128 subjects confirmed as having HSRs to quinolones and 42 found to be tolerant. Anaphylaxis was the most frequent entity in immediate HSRs and was most commonly induced by moxifloxacin. Patients were evaluated a median of 150 days (interquartile range, 60-365 days) after the reaction. Of patients who underwent ST and BAT, 40.7% and 70%, respectively, were positive. DPT with a quinolone was performed in 48 cases, giving results depending on the culprit drug: when moxifloxacin was involved, 62.5% of patients gave a positive DPT result to ciprofloxacin, whereas none reacted to levofloxacin. The risk of HSR was 96 times higher in subjects who reported moxifloxacin-induced anaphylaxis and 18 times higher in those reporting immediate reactions compared with clinical entities induced by quinolones other than moxifloxacin and nonimmediate reactions. The diagnosis of HSR to quinolones is complex. The use of clinical history is essential as a first step. BAT shows higher sensitivity than STs. DPTs can be useful for finding safe alternative quinolones.
dc.description.sponsorshipRETIC ARADYAL RD16/0006/0001, RD16/0006/0010, RD16/0006/0019, and RD16/0006/0030). I.D. is a clinical investigator (B0001-2017) from Consejería de Salud of the Andalusian government, Junta de Andalucía. N.P.-S. holds a Rio Hortega research contract (CM17/0014), and E.B. a Juan Rodes research contract (JR18/00049), both from the Institute of Health “Carlos III,” Spanish Ministry of Economy and Competitiveness (grants co-financed by the European Social Fund).
dc.description.versionSi
dc.identifier.citationDoña I, Pérez-Sánchez N, Salas M, Barrionuevo E, Ruiz-San Francisco A, Hernández Fernández de Rojas D, et al. Clinical Characterization and Diagnostic Approaches for Patients Reporting Hypersensitivity Reactions to Quinolones. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2707-2714.e2
dc.identifier.doi10.1016/j.jaip.2020.04.051
dc.identifier.essn2213-2201
dc.identifier.pmid32376487
dc.identifier.unpaywallURLhttps://riunet.upv.es/bitstream/10251/170289/7/DonaPerez-SanchezSalas%20-%20Clinical%20Characterization%20and%20DiagnosticApproaches%20for%20Patients%20Reportin....pdf
dc.identifier.urihttp://hdl.handle.net/10668/15518
dc.issue.number8
dc.journal.titleThe journal of allergy and clinical immunology. In practice
dc.journal.titleabbreviationJ Allergy Clin Immunol Pract
dc.language.isoen
dc.organizationHospital Universitario Regional de Málaga
dc.organizationCentro Andaluz de Nanomedicina y Biotecnología-BIONAND
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.page.number10
dc.provenanceRealizada la curación de contenido 17/03/2025
dc.publisherElsevier
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.relation.projectIDRD16/0006/0001
dc.relation.projectIDRD16/0006/0010
dc.relation.projectIDB0001-2017
dc.relation.projectIDCM17/0014
dc.relation.projectIDJR18/00049
dc.relation.publisherversionhttps://linkinghub.elsevier.com/retrieve/pii/S2213-2198(20)30410-4
dc.rights.accessRightsRestricted Access
dc.subjectAdverse drug reaction
dc.subjectAnaphylaxis
dc.subjectBasophil activation test
dc.subjectCiprofloxacin
dc.subjectDrug provocation test
dc.subjectHypersensitivity
dc.subjectLevofloxacin
dc.subjectMoxifloxacin
dc.subjectQuinolones
dc.subjectSkin tests
dc.subject.decsQuinolonas
dc.subject.decsMoxifloxacino
dc.subject.decsHipersensibilidad
dc.subject.decsAnafilaxia
dc.subject.decsPruebas Cutáneas
dc.subject.decsAntibacterianos
dc.subject.meshDrug Hypersensitivity
dc.subject.meshHumans
dc.subject.meshHypersensitivity, Immediate
dc.subject.meshLevofloxacin
dc.subject.meshQuinolones
dc.subject.meshSkin Tests
dc.titleClinical Characterization and Diagnostic Approaches for Patients Reporting Hypersensitivity Reactions to Quinolones.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number8
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format